Dengue - 67 Studies Found
| NOT_YET_RECRUITING |
: Identification of Risk Determinants of Dengue Transmission Through Landscape Analysis : : 2025-08-06 : A probabilistic risk model will be generated based on the variables of different natures used and maps will be built to identify the areas of greatest |
| Completed |
: Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine : Response To Dengue Exposure : 2025-08-06 : The rDEN3delta30/31-7164 vaccine is a live attenuated virus constructed by creating two deletions in the 3 UTR of the DENV3 Sleman/78 strain |
| Completed |
: Homologous Re-infection With Dengue 1 or Dengue 3 : Dengue : 2025-08-06 : Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5 |
| Completed |
: Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4) : Dengue : 2025-08-06 : Low dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 0. |
| Completed |
: Role of Vitamin D in Prevention of Dengue Haemorrhagic Fever and Dengue Shock Syndrome : Dengue Fever : 2025-08-06 : 2,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol 4,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol |
| COMPLETED |
: Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENV?30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002) : Dengue : 2025-08-06 : 0.5 mL SC dose of V181 |
| COMPLETED |
: The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever : Dengue Fever : 2025-08-06 : Ribavirin is an antiviral medication administered as part of the intervention arm.It will be provided orally in a dosage of 15 mg/kg body w |